Search Results for "moderate concentrate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for moderate concentrate. Results 11 to 20 of 505 total matches.

Intravenous Ciprofloxacin

   
The Medical Letter on Drugs and Therapeutics • Aug 09, 1991  (Issue 850)
Infect Dis, 163:1279, June 1991), and the drug is only moderately active against Streptococcus ...
Ciprofloxacin, previously available orally (Cipro - Medical Letter, 30:11, 1988) and for ophthalmic use (Ciloxan - Medical Letter, 33:52, May 31, 1991), is now the first fluoroquinolone antibiotic to become available in the USA in an intravenous (IV) formulation. Cipro I.V. (Miles) is being promoted as an alternative to third-generation cephalosporins, aminoglycosides, and other drugs used for treatment of serious infections.
Med Lett Drugs Ther. 1991 Aug 9;33(850):75-6 |  Show IntroductionHide Introduction

Roflumilast Cream (Zoryve) for Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024  (Issue 1711)
of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of mild to moderate ...
The FDA has approved a 0.15% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of mild to moderate atopic dermatitis (AD) in patients ≥6 years old. Roflumilast is the second PDE4 inhibitor to be approved in the US for treatment of AD; crisaborole (Eucrisa), which can be used in patients ≥3 months old, was the first. Roflumilast is available as Zoryve in a 0.3% cream for treatment of plaque psoriasis and a 0.3% foam for treatment of seborrheic dermatitis. It is also available in an oral formulation (Daliresp) for...
Med Lett Drugs Ther. 2024 Sep 16;66(1711):150-1   doi:10.58347/tml.2024.1711b |  Show IntroductionHide Introduction

Topical Pimecrolimus (Elidel) for treatment of atopic dermatitis

   
The Medical Letter on Drugs and Therapeutics • May 27, 2002  (Issue 1131)
in 260 adults with moderate to severe atopic dermatitis involving 5-30% BSA compared four concentrations ...
Pimecrolimus 1% cream (pim e kroe' limus; SDZ ASM 981; Elidel - Novartis) has been approved by the FDA for short-term and intermittent long-term treatment of mild to moderate atopic dermatitis in non-immunocompromised patients at least 2 years old.
Med Lett Drugs Ther. 2002 May 27;44(1131):48-50 |  Show IntroductionHide Introduction

Betaine for Homocystinuria

   
The Medical Letter on Drugs and Therapeutics • Jan 31, 1997  (Issue 993)
bottle. HYPERHOMOCYSTINEMIA AS A RISK FACTOR FOR VASCULAR DISEASE — Moderately increased concentrations ...
Betaine (Cystadane - Orphan Medical), an orphan drug, has recently been marketed for treatment of homocystinuria, a genetic disorder. Patients with homocystinuria frequently have premature atherosclerosis and thromboembolism, and may also have lens dislocations, skeletal abnormalities and mental retardation (SH Mudd et al in CR Scriver et al, eds, The Metabolic and Molecular Bases of Inherited Disease, 7th ed, New York:McGraw Hill, 1995, page 1279).
Med Lett Drugs Ther. 1997 Jan 31;39(993):12 |  Show IntroductionHide Introduction

Transdermal Buprenorphine (Butrans) for Chronic Pain

   
The Medical Letter on Drugs and Therapeutics • Apr 18, 2011  (Issue 1362)
opioid agonist buprenorphine in a transdermal formulation (Butrans – Purdue) for treatment of moderate ...
The FDA has approved the partial opioid agonist buprenorphine in a transdermal formulation (Butrans – Purdue) for treatment of moderate to severe chronic pain. Buprenorphine has been available in the US for years in parenteral formulations for pain and in sublingual tablets for opioid dependence.1 Transdermal buprenorphine has been available in Europe for several years.2
Med Lett Drugs Ther. 2011 Apr 18;53(1362):31-2 |  Show IntroductionHide Introduction

A New Ace Inhibitor and Two New Angiotensin Receptor Blockers For Hypertension

   
The Medical Letter on Drugs and Therapeutics • Nov 05, 1999  (Issue 1065)
metabolite perindoprilat, which reaches peak serum concentrations in 3 to 7 hours and is excreted mostly ...
Perindopril, the tenth angiotensin converting enzyme (ACE) inhibitor to be marketed in the USA, and telmisartan and eprosartan, the fifth and sixth angiotensin receptor blockers, have recently become available for treatment of hypertension.
Med Lett Drugs Ther. 1999 Nov 5;41(1065):105-6 |  Show IntroductionHide Introduction

Etrasimod (Velsipity) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023  (Issue 1690)
of moderate or strong inhibitors or inducers of these isozymes can affect serum concentrations of etrasimod ...
The oral sphingosine 1-phosphate (S1P) receptor modulator etrasimod (Velsipity – Pfizer) has been approved by the FDA for treatment of moderately to severely active ulcerative colitis in adults. It is the second oral S1P receptor modulator to be approved in the US for this indication; ozanimod (Zeposia) was the first.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):187-9   doi:10.58347/tml.2023.1690b |  Show IntroductionHide Introduction

Benzgalantamine (Zunveyl) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Apr 14, 2025  (Issue 1726)
, for treatment of mild to moderate dementia of Alzheimer's disease (AD). Immediate- and extended-release ...
The FDA has approved Zunveyl (Alpha Cognition), a delayed-release formulation of the prodrug benzgalantamine, for treatment of mild to moderate dementia of Alzheimer's disease (AD). Immediate- and extended-release formulations of the acetylcholinesterase inhibitor galantamine have been available in the US for years for treatment of AD.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):59-60   doi:10.58347/tml.2025.1726b |  Show IntroductionHide Introduction

Paroxetine (Brisdelle) for Hot Flashes

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2013  (Issue 1428)
(Brisdelle) for Hot Flashes reduction in the frequency of moderate-to-severe hot flashes from baseline ...
The FDA has approved a low-dose formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine mesylate (Brisdelle – Noven Therapeutics) for treatment of moderate-to-severe vasomotor symptoms associated with menopause. It is the first non-hormonal therapy to be approved for this indication. Paroxetine mesylate (Pexeva) and paroxetine hydrochloride (Paxil, and generics) are marketed in higher doses for treatment of depression and other psychiatric disorders.
Med Lett Drugs Ther. 2013 Oct 28;55(1428):85-6 |  Show IntroductionHide Introduction

Treatment of Onychomycosis

   
The Medical Letter on Drugs and Therapeutics • Oct 18, 2021  (Issue 1635)
to moderate uncomplicated onychomycosis ( ...
Onychomycosis is caused most commonly by Trichophyton rubrum or T. mentagrophytes. About 10% of all persons worldwide and 40% of those ≥60 years old are believed to have the disease. Risk factors include older age, diabetes, poor peripheral circulation, smoking, HIV infection, psoriasis, and immunosuppression. Left untreated, onychomycosis can cause nail plate destruction, ingrown nails, and (particularly in patients with diabetes) secondary infections. Guidelines on treatment of onychomycosis have been published.
Med Lett Drugs Ther. 2021 Oct 18;63(1635):164-8 |  Show IntroductionHide Introduction